sorry, we can't preview this file

...but you can still download Figure_S1.eps
Figure_S1.eps (1.22 MB)

Supplementary Figure – Infection rates and tolerability of three different immunoglobulin administration modalities in patients with PID

Download (1.22 MB)
figure
posted on 21.12.2021, 14:52 by Figshare Future Science GroupFigshare Future Science Group, Richard L. Wasserman, Sudhir Gupta, Mark Stein, Christopher J. Rabbat, Werner Engl, Heinz Leibl, Leman Yel

Supplemental Figure 1. Duration of causally related systemic (A) and local (B) AEs by treatment modality. During SCIG therapy, two events with a duration >10 days (infusion-site hematoma [25 days] and hemoglobin decreased [18 days]) were reported in two participants; during fSCIG therapy, eight events with a duration >10 days (nodule [n = 2; both 28 days], infusion-site mass [n = 1; 28 days], infusion-site erythema [n = 1; 28 days], blood pressure increased [n = 2; 17 and 28 days], lymphocyte count decreased [n = 1; 28 days], and white blood cell count decreased [n = 1; 28 days]) were reported in eight participants. AE: adverse event; fSCIG: facilitated SCIG; IVIG: intravenous immunoglobulin; SCIG: subcutaneous immunoglobulin.

Funding

Baxalta US Inc., a Takeda company

History